Skip to main content

Bausch Lomb Corporation(BLCO-T)
TSX

Today's Change
Real-Time Last Update
Day Low23.23
Day High23.33
Open:23.23
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Bausch Lomb Corporation

Select a category then submit the form to load news
INK Research
Director buying at Bausch + Lomb (BLCO)
Company Chart of BLCO
INK Research
Public market insider buying at Bausch + Lomb (BLCO)
Company Chart of BLCO
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
The Globe and Mail
Tuesday’s analyst upgrades and downgrades
Bell signage is seen at BCE Inc., headquarters in Montreal on Wednesday, May 7, 2025.
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
Business Wire
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Business Wire
Bausch + Lomb Announces Two Board of Directors Appointments
Business Wire
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
Business Wire
Bausch + Lomb to Participate in Citi Global Healthcare Conference
Business Wire
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
Business Wire
Bausch + Lomb to Hold Investor Day on Nov. 13
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Announces Third-Quarter 2025 Results
Business Wire
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13
Business Wire
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
Business Wire
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
Business Wire
Bausch + Lomb Announces Board Changes
Baystreet
Stocks in play: Bausch + Lomb Corporation
Business Wire
Bausch + Lomb to Participate in Upcoming Investor Conferences
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Short sales on the TSX: What bearish investors are betting against
The TMX Market Centre is shown in Toronto, Wednesday, Sept. 11, 2024.

Profile

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.